Revenues fall at Sensodyne maker Haleon after weaker painkiller sales
Shares were lower in early trading on Thursday as a result.
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
Consumer healthcare firm Haleon has revealed a surprise dip in revenues for the latest quarter as it was impacted by weaker sales of painkillers.
Shares in the Sensodyne and Voltaren maker were lower in early trading on Thursday as a result.
Haleon told investors that revenues declined by 0.6% to £2.78 billion for the three months to September 30, compared with the same period last year.
It came as the company revealed sales in its pain relief business dropped by 1.3% to £628 million for the period.
The group said it was impacted by mid-single digit decline for Panadol, while Voltaren sales were broadly flat.
Total revenues were also impacted by the sale of some of its non-core brands over the past year, including ChapStick which it sold to private equity firm Yellow Wood Partners.
Having achieved organic revenue and organic profit growth of 4.4% and 9.7% respectively year-to-date, we are well on track to deliver our full-year 2024 guidance
Nevertheless, the group saw organic revenues rise by 6.1% for the quarter, supported by a 3.3% increase in pricing.
It said its biggest brands helped drive a 5.4% rise in organic revenues, highlighting particularly strong performances from Sensodyne, Parodontax and Advil.
Meanwhile, organic profits grew by 7.4% for the quarter.
Chief executive Brian McNamara said: “Third quarter trading was strong with momentum across the business underpinned by the strength of our brand portfolio driving market share gains.
“Oral health was again a particular highlight, with organic revenue up high-single digit as Sensodyne and Parodontax continued to drive growth.
“Having achieved organic revenue and organic profit growth of 4.4% and 9.7% respectively year-to-date, we are well on track to deliver our full-year 2024 guidance.”
Shares in the company were down 2.3% in early trading.